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Abstract
Background: Right ventricular failure (RVF) and -support is associated with poor results. We aimed for a new
approach of right - sided assistance bypassing the right ventricle and pulmonary circulation in order to better
decompress the right ventricle and optimize left ventricular filling.
Methods: From a microaxial pump (Abiomed), a low resistance oxygenator (Maquet and Novalung) and two
cannulas (28 and 27 Fr) a system was set up and evaluated in an ovine model (n = 7). Connection with the heart
was the right and left atrium. One hour the system was operated without RVF and turned of again. Then a RVF
was induced and the course with the system running was evaluated. Complete hemodynamic monitoring was
performed as well as echocardiography, flow measurement and blood gas analysis.
Results: The overall performance of the system was reliable. Without RVF no relevant changes of hemodynamics
occurred; blood gases were supra normal. In RVF a cardiogenic shock developed (MAP 35 ± 13 mmHg, CO 1,1 ±
0,7 l/min). Immediately after starting the system the circulation normalized (significant increase of MAP to 85 ± 13
mmHg, of CO to 4,5 ± 1,9). Echocardiography also revealed right ventricular recovery. After stopping the system,
RVF returned.
Conclusions: Bypassing the right ventricle and pulmonary circulation with an oxygenating assist device, which
may offer the advantages of enhanced right ventricular decompression and augmented left atrial filling, is feasible
and effective in the treatment of acute RVF. Long time experiments are needed.
Keywords: Right ventricular failure, surgical treatment, assist device, pulmonary circulation, bypass, gas exchange,
perfusion route
Background
Right ventricular failure is an often deleterious condition
and associated with a high mortality [1,2]. The patho-
physiology of RVF is complex, reflecting the challenges
in treatment of RVF [3]. Surgical options to treat RVF
are very limited and besides transplantation the only
proven surgical option is a right ventricular exclusion
with a “fontanisation” of blood circulation [4,5]. Con-
ventional implantation of assist devices in RVF shows
poor long-term results [6], what in our point of view is
due to the fact that major mechanisms of RVF are not
eliminated despite mechanical circulatory assistance. An
important mechanism, which leads to low cardiac out-
put in RVF, is the reduced trans-pulmonary blood flow
with reduced left atrial-, and consecutively left ventricu-
lar filling. The major determinant of right ventricular
performance is right ventricular afterload. In previous
studies on RVF we focused on a passive (and oxyge-
nated) decompression of the pulmonary circulation into
the left atrium and could demonstrate significant hemo-
dynamic improvement [7,8]. Taking all this into account
we hypothesized that an optimal assist system to treat
RVF should take over the stroke work of the right
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ventricle on the one hand, and should both reduce right
ventricular afterload and augment left ventricular filling
by bypassing the pulmonary circulation into the left
atrium on the other hand. Based on the fact, that this
system bypasses the lung a gas exchange within the sys-
tem is essential because otherwise severe hypoxemia
would result. We designed such a system with forth-
coming potential for an ambulatory application and
named it “Right-Left Assist Device” (R-L AD). This
device was evaluated in an open chest animal model of
acute RVF assessing feasibility, efficacy to treat RVF and
possible adverse effects.
Methods
I Development and characterisation of the system
I a) Configuration and set up
Our aim was to create an extracorporeal active pump
system to deliver blood from the right atrium directly to
the left atrium. To prevent hypoxia an artificial gas
exchange system had to be integrated. Therefore the
systems’ main components consisted of a blood pump,
an oxygenator and cannulas connecting the system with
the heart. [Figure 1: Arrangement scheme of the R-L
AD]
I b) Pump
The Impella® Elect 600 microaxial pump (Abiomed Eur-
ope GmbH, Aachen, Germany) was used to generate
active blood flow. This miniaturized rotary blood pump
has a diameter of 12 mm, a length of 40 mm and a
weight of 6 g. The inner volume of the pump is only 1,5
mL and the inner artificial and blood contacting surface
is 15,9 cm2. At a maximal speed of 33000 revolutions
per minute (rpm), a flow of up to 6 L/min can be gener-
ated. All control parameters are displayed continuously
on the external driving console [9,10].
I c) Gas-exchange unit
In order to utilise maximum performance of the pump,
“low resistance” oxygenators with the smallest possible
resistance were used. Initially we chose the Quadrox®
(Maquet, GmbH & Co KG Rastatt, Germany), which
includes an effective heat exchanger. This oxygenator
bears a 1,8 m2 polymethylpentene diffusion membrane
and can be run with a blood flow rate from 0.5 to 7 L/
min. The Quadrox® system was used in 2 animals. After
the first 2 experiments we switched to oxygenator to the
Novalung® - iLA membrane oxygenator (Novalung
GmbH, Hechingen, Germany) due to the relevant degree
of unhandiness of the Quadrox® system (bigger size and
weight, need for a gas blender). The Novalung®’s diffu-
sion membrane of polymethylpentene has a surface of
1,3 m2 and is housed in a rather small rigid 15 × 15 cm
polyethlen box. It is intended for a blood flow of 0,5 to
4,5 L/min.
I d) Cannulas, connections and complete system
A 28 Fr cannula (Edwards Lifesciences®, USA) with a
length of 88 cm was used for evacuating the blood out
of the right atrium. This cannula was connected via a 3/
8 (inch) flexible tube (Raumedic®; Helmbrechts, Ger-
many) of 5 cm length to the microaxial pump. On the
other side of the pump’s connector another 5 cm long
3/8 tube connected to the gas exchange unit. Following
the gas exchange unit another 5 cm of flexible tube is
connected to a 27 Fr cannula ("Bio-Medicus” Femoral
Venous Cannula, Medtronic®, USA) of 70 cm length
delivering the blood into the left atrium. [Figure 2:
Photograph of the system ("R-L AD”)]
II Experimental evaluation in the animal model
After having completed the setup of our “Right-Left
Assist Device”, we investigated it in seven animals. In
principle the experiments should characterize the system
with and without RVF.
II a) Animals and anaesthesia
Seven female Rhoensheeps of 65 (+/- 4) kg were used in
this study. The animal research protocol was approved
by the local authorities (Lanuv in Recklinghausen; Ref
No.: 8.87-51.04.20.09.307). Animals were treated accord-
ing to the “Guide for the care and use of Laboratory
animals” published by the US National Institutes of
Health (National Institutes of Health publication no. 85-
23, revised 1996). After premedication, anesthesia was
maintained by continuous intravenous application of
pentobarbital and fentanyl Animals were intubated and
ventilated initially with 100% oxygen. Tidal volumes
were adjusted to 10 ml/kg in order to maintain a pCO2
of 4,65 - 5,32 kPa according to the blood gas analyses.
Oxygen concentration was maintained at 40%. Single
shot antibiotic prophylaxis was administered (Cefurox-
ime 1,5 g) before skin incision. Fluid (Ringers lactate)
was given at a rate of 20 ml/kg/h. The temperature of
the animal was maintained with a heating blanket and
an infrared lamp. During the operation of the oxygena-
tors the Quadrox® system was run with a flow rate of 4
L/min and a FiO2 of 0.6 via a gas blender. The
Figure 1 Arrangement scheme of the R-L AD; note, that the
main principle of the system is bypassing the right ventricle
and the pulmonary circulation. Delivery of oxygenated blood to
the left atrium results in a controlled oxygenated right to left shunt.
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Novalung® was run with 4 L/min of oxygen during the
whole experiment.
II b) Instrumentation and surgical preparations
All animals received a central venous line (Quad-Lumen
Indwelling Catheter, Arrow®, USA) via the left internal
jugular vein. Both of them were dissected surgically. A
Swan-Ganz catheter (7.5-F, Model VS 1721; Ohmeda,
UK) was inserted into the proximal pulmonary artery
from the left - sided jugular vein. Another balloon
catheter ("Berman” Angiographic Catheter 6 Fr 60 cm;
Arrow®, USA) was advanced into the right ventricle
from the right jugular vein to determine right ventricu-
lar pressures. The left - sided groin was surgically dis-
sected with exposition of the femoral vessels. Using
Seldingers technique a femoral arterial line (18 G,
Vygon, Germany) was placed into the left femoral artery
under direct vision.
A small left thoracotomy in the fourth intercostal
space was performed. After incising the pericardium, the
left atrium was exposed and pulmonary artery was dis-
sected. A catheter (18 G, Vygon®, Germany) was
inserted into the left atrium and secured with a suture.
All catheters were connected to fluid - coupled pressure
transducers. An ultrasonic flow probe (24 mm
Transsonic®; USA) was placed around the proximal des-
cending aorta. After complete heparinization a purse-
string suture was placed on the free lateral wall of the
left atrium. The 27 Fr outflow cannula was introduced
into the left atrium after incision of the wall, clamped
and suture secured. Thereafter the 28 Fr inflow cannula
was positioned in the right atrium via the right jugular
vein under echocardigraphic control and also clamped.
As a last step the whole system was carefully deaired
and connected with the cannulas. The pump speed was
adjusted to approximately 29.000 rpm resulting in a
flow of 4,2 l/min, controlled by an ultrasonic flow probe
(Transsonic®, USA) around the 3/8 inch tube.
II c) Right ventricular failure model
Banding of the very distal main pulmonary artery was
performed to achieve RVF. We used a custom-made
apparatus to reduce the diameter of the pulmonary
artery very slowly by a screwing mechanism. The band-
ing was persistent. RVF following pulmonary artery
banding was defined as a profound decrease in systemic
blood pressure (MAP < 2/3 of baseline) and depressed
cardiac output (CO < 2/3 of baseline). Additionally right
ventricular function was judged by visual inspection.
II d) Echocardiography
Transthoracic echocardiography was performed in all
experiments using the Vivid E 9 System with the M5S
Transducer (GE Vingmed, Germany) at 2.5 MHz. In a
four chamber equivalent view, the right ventricle was
imaged in standard two-dimensional mode for online
estimation of systolic function by global morphology,
right ventricular diameter (RVd) measured at the tricus-
pid annulus and tricuspid annular plane systolic excur-
sion (TAPSE) in M-mode. TAPSE ≥ 18 mm was
regarded as normal. In addition right ventricular failure
was estimated by the immediate occurrence of ventricu-
lar septal shift to the left during the acute increase in
right ventricular afterload. A cine loop of at least four
consecutive cardiac cycles was stored for off-line analy-
sis by Echopac software (GE Vingmed, Germany).
II e) Experimental Protocol
The animal experiment should prove the principal feasi-
bility of our new approach and allow a characterization
of the system during different circulatory conditions.
Therefore measurements were taken at predetermined
times. These measurements ("data acquisition” (DA))
included complete hemodynamic monitoring, flow mea-
surement and blood gas analysis. After having finished
all surgical preparations and having the system con-
nected (but clamped) a “baseline I” measurement was
performed. In a first step the running R-L AD was eval-
uated during a period of normal circulation. This was
followed by a “baseline II” with an again turned off and
clamped R-L AD system. Thereafter RVF was induced
and characterized. This was followed by “treatment of
Figure 2 Photograph of the system ("R-L AD”); it consists of
the pump (top left), the oxygenator (top right) and the
cannulas (bottom).
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RVF” by switching on the R-L AD during persistent pul-
monary artery banding. To exclude meantime changes
in right ventricular function or any other circulatory
adaptations, the R-L AD was switched off again to char-
acterize the degree of the “recurrent RVF (Re-RVF)”.
The echocardiographic investigations (E) were per-
formed during unaffected circulation, during RVF and
during the “treatment of RVF”.
At the end animals were euthanized with an overdose
of pentobarbital and fentanyl. A macroscopic autopsy of
the entire carcass was carried out with focus on the
heart, lungs and kidneys. [Additional file 1: Experimental
protocol]
II f) Data acquisition and statistical analysis
Data were collected using the Datex AS-3 Compact
Monitor (Datex Engstrom, USA) and digitally recorded
during the study. Flow measurements were also col-
lected and digitally recorded during the study. Data are
expressed as means +/- SD. Statistical analyses were per-
formed with version 18 of SPSS (SPSS, USA). A Stu-
dent’s 2 tailed paired t test was used. All statistical
analyses were performed to a level of significance of
0,05.
Results
a) General results
All animals survived the whole experiment until recur-
rence of RVF with the R-LAD turned off again. During
the next 30 min after re-initiating RVF 4 of the 6 ani-
mals died due to severe cardiogenic shock. The remain-
ing 2 animals also suffered severe cardiogenic shock
and therefore had to be euthanised. Surgical prepara-
tions were uneventful. The placement of the cannula
from the jugular vein into the right atrium was uncom-
plicated under echocardiographic guidance. Insertion of
the left atrial cannula via the lateral thoracotomy also
proved to be easy and safe. Only very little contamina-
tion of air was detectable during the insertion of the
cannula into the left atrium. Cardiopulmonary bypass
was not necessary at any time of the operation. Neither
catecholamines had to be administered in any experi-
ment nor relevant arrhythmia occured. During the
whole experiment urine output maintained at normal
levels except the longer lasting recurrent RVF. The R-L
AD was easily manageable: operation of the device was
completely without dysfunction. It run stable without
any relevant alterations. The aimed flow of 4,2 l/min
could be delivered at pump speeds of 29.000 rpm
despite the different conditions during the course of the
experiment. Gas exchange worked very well with both
types of oxygenators. [Figure 3: Operative view of the
R-L AD’s] The visible “collapse” of the right ventricle
indicated effective decompression during system opera-
tion without RVF. In RVF tachycardia with severe
changes in the electrocardiogramm (new right bundle
branch block with ST-segment depression and inversed
T-wave) occurred with an obviously severe overdisten-
sion of the right ventricle confirmed by echocardiogra-
phy (E 2). When the R-L AD was switched on, the right
ventricle recovered nearly immediately. “Eyeballing”
again showed a collapsing aspect of the right ventricle
resembling its morphology without RVF and pump-sup-
port as shown above. The electrocardiogramm normal-
ized with a delay of some minutes. With the R-L AD
turned off again, RVF reoccurred with the same overdis-
tended aspect of the right ventricle and changes in the
electrocardiogram.
b) Hemodynamics and flows
During the experiments all hemodynamic parameters
and flows were digitally recorded. An overview of the
most relevant data is given in Additional file 2, Table
S2. [Additional file 2: Relevant data from the
experiments]
“R-L AD”
In this section the effect of the system in an unaffected
circulatory status was studied. The overall hemody-
namics stayed completely stable. No relevant alteration
of the cardiac output was detectable with similar arterial
pressures compared to the baseline measurements. The
only alterations were a significant decrease of the CVP
from 8 to 3-4 mmHg with an inversely proportional
increase of the LAP from 9 to 20-23 mmHg. Amazingly
right ventricular filling pressures decreased only slightly
(ns). The pO2 increased significantly from 13 to 29-30
kPa, also leading to an elevated mixed venous oxygen
saturation.
“RVF”
Right ventricular failure demonstrated severe with a sig-
nificant decrease of CO from 3.9 to 1.1 L/min and con-
cordant of the MAP from 75 to 35 mm Hg. CVP rose
up to 19 whereas the LAP decreased to 3-5 mmHg.
Especially the latter is one of the most important fea-
tures of RVF with decreased left sided filling (serial ven-
tricular interdependence). The right ventricular filling
Figure 3 Operative view of the R-L AD; Left: with the
Quadrox®, Right: with the Novalung®.
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pressures initially increased, but with the severity of RVF
decreased again. The mixed venous oxygen saturation
declined significantly from 66 to 39% indicating a severe
cardiogenic shock.
“Treatment of RVF”
all signs of cardiogenic shock disappeared immediately
by turning on the R-L AD. CO significantly recovered
to 5.1 (+/- 1,5) l/min at most, the MAP, after an initial
overshoot up to 85 mmHg, normalized around 78 (+/-
8) mmHg, which is significant in comparison to “RVF”.
The mixed venous saturation also normalized to 70 (+/-
4.4) % with an arterial pO2 around 30 kPa. The major
reason for the overall recovery (with an interrupted
vicious circle of the RVF) is augmented left atrial filling
in conjunction with right sided decompression: the CVP
declined significantly from around 18 to 4 mm Hg, but
more important the LAP rose from around 4 to 22 mm
Hg. This hemodynamic alteration is clearly caused by
the R-L AD because blood is pumped from the right
atrium to the left atrium.
“Re-RVF”
As fast as RVF disappeared when the R-L AD was acti-
vated, RVF returned when the system was switched off
again. All parameters indicated a recurrent cardiogenic
shock. Especially right sided congestion and reduced left
atrial filling reoccurred with a CVP around 18 and a
concordant drop of the LAP down to around 5 mmHg.
[Figure 4: Diagram of the time course of MAP and
RVP]; [Figure 5: Diagram of the time course of CVP
and LAP]; [Figure 6: Diagram demonstrating the rela-
tionship of the R-L AD flow with CO and SvO2]
c) Echocardiography
Baseline right ventricular systolic function (TAPSE(E 1):
20 ± 1.9 mm) and diameter values (RVd(E 1): 29 ± 3.2
mm) were within normal ranges. The heart presented
good overall contractility. Within a minute of raised
afterload (RVF) the right ventricle showed steady loss of
systolic function and growing global dilatation, while the
left ventricle appeared increasingly volume-depleted
causing ventricular septal shift to the left. The right
Figure 4 Diagram of the time course of MAP and RVP. Note the
nearly unchanged pressures despite the running R-L AD between
baselines I and II. In RVF the MAP normalizes when the R-L AD is
switched on (after initial overshoot).
Figure 5 Diagram of the time course of CVP and LAP during
the experiment demonstrating the efficacy of bypassing the
right ventricle and pulmonary circulation by the R-L AD
(decompression of right heart with augmentation of left sided
filling).
Figure 6 Diagram demonstrating the relationship of the R-L
AD flow with CO and SvO2 during the experiment: A complete
circulatory recovery with normalization of the SvO2 is
achieved.
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ventricular systolic function was severely reduced
(TAPSE(E 2): 8 ± 1.0 mm) with severe dilatation right
ventricle (RVd(E 2): 42 ± 2.1 mm). After the R-L AD
was initiated the septal shift reversed quickly. Systolic
function recovered gradually, but remained mildly
impaired (TAPSE(E 3): 15 ± 1.7 mm). The right ventri-
cular size returned to above normal values (RVd(E 3):
23 ± 2.5 mm), while left ventricular filling appeared nor-
malized during pump support. Tissue doppler imaging
investigations (data not shown) further confirmed a
recovery from a severely injured right ventricle after
turning the R-L AD on. [Additional file 3: Echocardio-
graphic parameters]
d) Autopsy
Neither relevant intracavitary - nor system thrombus
formation was found. A gross examination of the lungs,
the heart and kidneys did not reveal any signs of throm-
bosis or infarctation. The macroscopic inspection of
abdominal cavity did not show any abnormalities.
Discussion
Right ventricular failure often exhibits the final phases
of various diseases e.g. COPD, pulmonary hypertension
or ARDS [11-13]. In cardiac surgery RVF is a frequent
cause for postoperative cardiogenic shock and is asso-
ciated with a higher mortality than left ventricular fail-
ure [14-16]. Although great progress has been made in
the field of mechanical circulatory support in general,
right - sided circulatory assist is still associated with
poor results [15,16]. Still some relevant issues in
mechanical treatment of RVF are unclear: Neither the
role of decompression of the pulmonary circulation in
mechanical right ventricular assistance is defined nor
its effects on remodeling mechanisms of the RV or
pulmonary circulation. Furthermore there is no evi-
dence which right ventricle (and the needed duration)
can be assisted to full recovery in which underlying
disease.
In this context we aimed for a new approach to assist
the failing right ventricle by oxygenated bypassing of the
pulmonary circulation from the right to the left atrium.
This approach, even though initially medically challen-
ging, combines the following advantages. At first the
stroke work of the right ventricle can be fully taken over
by the system. Secondly, by not returning blood into the
pulmonary circuit right ventricular afterload is dimin-
ished and moreover reduced transpulmonary blood-flow
with decreased left sided filling (so called serial ventricu-
lar interdependence) is overcome by returning blood
into the left - sided cavities. Additionally the use of a
gas exchange element in the system allows optimal
adjustment of oxygenation and decarboxylation, which
is often crucial in RVF.
We designed such a system under the aspect, that a
minimally invasive or even percutaneous implantation
should be realizable in the near future. In the present
study we investigated this device regarding feasibility, its
efficacy in the treatment of RVF and side-effects. An at
least in part open-chest implantation of the cannulas
and instrumentation was chosen to simplify the investi-
gations in a hypertension induced RVF. Our experi-
ments proved, that the implantation of the system is
easy to perform and a safe procedure without the need
for cardiopulmonary bypass or extensive surgical proce-
dures. Once the system was implanted, there was no
relevant detoriation of circulatory parameters detectable
neither without nor with pumping of 4-5 liters per min-
ute. This demonstrated an overall excellent tolerance of
the “Right-Left Assist Device” what seems to be impor-
tant especially for weaning.
Experimentally we could demonstrate an excellent
efficacy of the R-L AD to treat RVF. Activating the R-L
AD led to a very fast recovery from cardiogenic shock.
Whereas in the “RVF” state CVP and RVP increased,
LAP and MAP decreased. With activation of the R-L
AD these pressures reversed or even behaved reciprocal,
what was interpreted as efficient overcoming of serial
ventricular interdependence (reduced transpulmonary
bloodflow to the left atrium) and also efficient reduction
in right ventricular afterload. The gas exchange para-
meters demonstrated excellent and especially easy to
alter without the necessity of aggressive ventilation. The
findings of an excellent right ventricular decompression
with immediate recovery of right ventricular function
were also confirmed by echocardiography.
We could not detect any relevant negative side effects.
There was virtually no contamination with air or gas
respectively. In the post mortem examinations we could
not find any signs of thrombus formation or peripheral
embolism.
To our knowledge this is the first systematic investiga-
tion regarding the treatment of RVF by circumventing
pulmonary circulation. Only Herlihy et al reported in
2009 an attempt in two patients to perform an ECMO
support via Tandem Heart System’s Catheters from the
right atrium transseptal into the left atrium [17].
Although their primary aim was an improved delivery of
oxygen to the brain and the avoidance of left ventricular
distension by a veno-arterial ECMO (what they
achieved), they concluded, that “the catheter system can
provide novel and perhaps superior vascular routes for
the delivery of ECMO”. They did not highlight the
pathophysiologic advantages of this perfusion route in
RVF. In contrast we consider the approach of Wang
and Zwischenberger, which introduced their concept of
an “Ambulatory Oxygenator Right Ventricular Assist
Device for Total Right Heart and Respiratory Support”
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in 2007 [18] more suited for chronic pulmonary sup-
port, because right ventricular recovery is not intended
primarily. Nevertheless in 2011 Camboni published an
experimental study with creation of an ASD and ECMO
assistance in a model of also hypertension induced RVF
[19]. He could demonstrate an overall beneficial effect
of this approach, although the creation and the adjust-
ment of various parameters like the size of the ASD and
tricuspid regurgitation appeared difficult. The pathophy-
siologic background of this study is similar to ours,
namely that shunting of oxygenated blood from the
right to the left atrium avoids the overall deleterious
effects of RVF. Compared to this study a much better
control of all parameters like the amount of shunted
volume or the degree of gasexchange seems to be possi-
ble by a R-L AD. Our approach of a thoracotomy to the
left atrium was most of all chosen because it was neces-
sary anyway for the RVF-model of pulmonary artery
banding and thereby the easiest way to introduce a can-
nula into the left atrium. Nevertheless a non-thoractomy
introduction of the cannula into the left atrium was pre-
liminary already realized by a transvenous-transseptal
approach. A matter of current investigation is a transve-
nous double lumen cannula which collects blood inside
the right atrium and returns it transseptally into the left
atrium by only one cannula inserted through the right
internal jugular vein. The relative complexicity of our
approach (in comparison to a delivery into the pulmon-
ary artery) did not show any problems. The need for
anticoagulation with these types of components is not
really increased because the intended ACT should be
180 seconds. On the other hand this slightly increased
complexicity (in comparison to conventional v-v or v-
pa, but not v-a ECMO’s) offers a greatly improved
hemodynamic and respiratory control.
Limitations
In this experimental study no high fidelity cardiopul-
monary recording was used. The investigation of other
RVF models and the determination of long term results
are a matter of further investigations. Also a real com-
parison of our new approach with classical ECMO and
RVAD seems necessary.
Conclusion
We were able to demonstrate, that our newly developed
“Right-Left Assist Device” is a feasible technique without
relevant side effects in the acute setting. Operation of
the system without RVF does not lead to significant cir-
culatory changes whereas it is extremely effective in
restoring normal hemodynamics in acute RVF. This
approach with enhanced decompression of the right
ventricle and improved left atrial filling might be further
developed into a new option for the mechanical assis-
tance of the failing right ventricle with the aim of
recovery.
Additional material
Additional file 1: Experimental protocol: chronological order of
measuring times. Da = complete data acquisition, E =
echocardiographic examination.
Additional file 2: Relevant data from the experiments according to
protocol.
Additional file 3: Echocardiographic parameters measured
according to the protocol demonstrating right ventricular recovery
by the “treatment of RVF”.
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